0001104659-20-042771.txt : 20200403
0001104659-20-042771.hdr.sgml : 20200403
20200403090218
ACCESSION NUMBER: 0001104659-20-042771
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200402
FILED AS OF DATE: 20200403
DATE AS OF CHANGE: 20200403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ricardo Alonso
CENTRAL INDEX KEY: 0001768722
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37926
FILM NUMBER: 20771817
MAIL ADDRESS:
STREET 1: C/O RA PHARMACEUTICALS, INC.
STREET 2: 87 CAMBRIDGEPARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ra Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001481512
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262908274
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 87 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: (617) 401-4060
MAIL ADDRESS:
STREET 1: 87 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
4
1
a4.xml
4
X0306
4
2020-04-02
1
0001481512
Ra Pharmaceuticals, Inc.
RARX
0001768722
Ricardo Alonso
C/O RA PHARMACEUTICALS, INC.
87 CAMBRIDGEPARK DRIVE
CAMBRIDGE
MA
02140
0
1
0
0
See Remarks
Common Stock
2020-04-02
4
D
0
2973
48.00
D
0
D
Stock Option (Right to Buy)
0.84
2020-04-02
4
D
0
2857
0
D
2022-06-14
Common Stock
2857
0
D
Stock Option (Right to Buy)
2.87
2020-04-02
4
D
0
14285
0
D
2024-12-11
Common Stock
14285
0
D
Stock Option (Right to Buy)
2.87
2020-04-02
4
D
0
30000
0
D
2025-12-10
Common Stock
30000
0
D
Stock Option (Right to Buy)
5.60
2020-04-02
4
D
0
31428
0
D
2026-08-16
Common Stock
31428
0
D
Stock Option (Right to Buy)
16.64
2020-04-02
4
D
0
60000
0
D
2027-02-01
Common Stock
60000
0
D
Stock Option (Right to Buy)
7.33
2020-04-02
4
D
0
26250
0
D
2028-02-01
Common Stock
26250
0
D
Stock Option (Right to Buy)
21.00
2020-04-02
4
D
0
107000
0
D
2029-02-01
Common Stock
107000
0
D
Restricted Stock Units
2020-04-02
4
D
0
4375
0
D
Common Stock
4375
0
D
Includes 2,973 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020.
Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit.
The Reporting Person is Chief Technology and Innovation Officer and Head of Research.
/s/ David C. Lubner, Attorney-in Fact for Alonso Ricardo
2020-04-03